Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Recruiting × cabazitaxel × Clear all

Phase

Phase 2 4 Phase 3 3 Phase 2/3 1 Phase 1/2 1 Phase 1 1

Status

Active not recruiting 3 Terminated 2 Suspended 1 Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms, Castration-Resistant 1

Interventions

pembrolizumab 94 Cyclophosphamide 69 Carboplatin 55 fludarabine 50 Injections 50 Bevacizumab 43 Gemcitabine 37 venetoclax 34 Paclitaxel 34 Nivolumab 34 Cisplatin 33 Specimen Handling 32 Dexamethasone 32 Magnetic Resonance Spectroscopy 31 Docetaxel 30 Biopsy 28 toripalimab 22 Temozolomide 22 Pemetrexed 22 atezolizumab 21 Irinotecan 21 Azacitidine 21 Oxaliplatin 20 Fulvestrant 20 Capecitabine 20 abemaciclib 19 Rituximab 18 Fluorouracil 18 Radiotherapy 17 Cetuximab 17

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06353386 2026-03-13

MK-5684-01A

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡